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ABSTRACT 
Introduction of Literature: Air pollution has been related to acute and chronic respiratory 
health effects in asthmatics for a number of years. These chronic exposures to high levels of 
traffic density and particulate matter (PM 2.5) lead to significant decrements in lung function. 
Historically, the city of Pittsburgh has been known to have high levels of air pollution, (6th 
Highest per American Lung Association) – but little to no analysis has been done on this 
population to document the respiratory health impact of traffic density levels and particulate 
matter exposure.  
Methods: The sample population of this study was comprised of Registry Participants from The 
Asthma Institute at The University of Pittsburgh Medical Center in Pittsburgh, PA. Patients that 
have had lung function tests recorded by the Asthma Institute, and also live at residences that 
were able to be geocoded by the Department of Environmental and Occupational Health at the 
University of Pittsburgh Graduate School of Public Health were included in the final analysis (n= 
452). We used the LUR to create a spatial smoothed surface of PM concentrations across the 
area, then averaged, for each residence, the 100-m cell centroid predictions from this surface that 
fell within 300-m of each home.  Regulatory data was used to adjust these measures to estimate 
PM at each location for the month prior to lung function testing. We used linear regression 
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analysis to determine: A) the linear relationship between exposures and lung function tests; and 
B) the association between exposures with road density exposures and their respective quartiles.
We adjusted for race, age, and sex as confounders.  
Limitations: There are some expected limitations to the findings of this study. First, because this 
is a cross-sectional study, we cannot assume any causation. Additionally, exposures to PM and 
traffic density are roughly estimated through GIS which may contain errors, and there are no 
indoor exposure readings available. Moreover, single measurements of lung function tests 
provide only a snapshot of asthma severity at the time they were recorded.  
Results: The univariable analysis found living in areas with higher road density levels is 
associated with reductions in lung function, which may imply that asthmatics living in the 
Pittsburgh area that are exposed to higher levels of air pollution experience steeper airway 
function declines. However, when adjusting for the confounders of race, age, and sex, there was 
no true association found between the PFT test results and road density or PM2.5 exposure. 
Public Health Significance: From a public health perspective, this study may help planning 
committees better understand and recognize the necessity to monitor traffic related air pollution 
mechanisms in specific areas of Allegheny County.  Individuals are exposed to manmade and 
natural air pollutants at all times of the day throughout the course of their lifetime. An individual 
that is exposed to larger amounts of air pollution, and has clinical asthma, may benefit from 
being knowledgeable about the effects of air pollution on his or her body, and how to limit their 
daily exposures.  
v 
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1.0  INTRODUCTION 
Respiratory health is a multi-faceted, complex issue whose improvement often requires 
knowledge of a patient’s medical and environmental history. In the State of Pennsylvania more 
than 9% of all adults have asthma. While the air in Pittsburgh, Pennsylvania is cleaner than it has 
been in the past few decades, the American Lung Association ranks the city as the one of the 
most polluted metropolises in the country. According to the American Lung Association’s 2014 
State of the Air Report, Pittsburgh is ranked number 6 for year-round particle pollution and 
short-term particle pollution.(American Lung Association, 2014b) According to the report, 
although air pollution levels have decreased in recent years, overall air quality has decreased 
since the 2013 report with increased PM exposure levels – giving the city a rating of F for air 
quality. In Allegheny County there are 265,000+ adults and children with asthma and the 
149,00+ individuals with Chronic Obstructive Pulmonary Disease (COPD), and our current air 
quality places them at increased risk of further respiratory health complications. Several studies 
have associated higher levels of PM exposures with acute respiratory illness in people, as 
demonstrated by increased respiratory symptoms or hospitalizations. 
The aim of this study is to examine the respiratory health impact of road density levels 
and particulate matter exposure by analyzing survey data collected at the Asthma Institute at the 
University of Pittsburgh Medical Center (UPMC). This thesis will begin with a review of the 
literature, examining each of the specific areas of interest to the study, that is, fine particulate 
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matter (PM2.5) and road density exposures. The document will then describe survey 
methodology, study participants, and study measures. It will also describe the data collection 
processes and methods of analysis. The thesis will report results of the analysis and provide an 
interpretation of findings. Finally, the conclusion will provide recommendations and implications 
drawn from the data. 
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2.0  REVIEW OF LITERATURE 
2.1 ASTHMA AND AIR POLLUTION 
Asthma is defined as chronic lung disease that narrows and inflames the airways, causing 
periods of wheezing, chest tightness, shortness of breath, and coughing. It affects people of all 
ages but is often diagnosed during childhood. In the United States, 25 million people (8% of the 
overall population) have been diagnosed asthma, and 7 million of these people are children 
(National Heart Lung Blood Institute, 2014).  Although the exact cause of asthma is unknown, 
genetics, allergies, respiratory infections, and environmental pollutants may play significant roles 
in adult-onset asthma (American Lung Association, 2014a). When an individual’s airways react, 
the muscles around the airways tighten, narrowing the airways and reducing airflow into the 
lungs. Asthma attacks are also identified as flare-ups or exacerbations. There is no cure for 
asthma, but treatment through medication may help individuals with asthma better manage its 
symptoms, and reduction of outdoor exposures that trigger exacerbations may allow them to live 
more normal, active lives.  
To better interpret results of this study it is important to understand the biological 
processes that occur when individuals with asthma are exposed to air pollution. In areas that have 
high concentrations of pollution, direct irritant and inflammatory effects on airway neurological 
receptors and epithelium have been observed (Guarnieri & Balmes). However, even in areas with 
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lower concentrations of pollution, such as those in high income countries like the United States, 
pollutants such as PM2.5, nitrogen dioxide, and ozone levels induce airway inflammation and 
airway hyper-responsiveness. (Kirby, Hargreave, Gleich, & O'Byrne, 1987; Lippmann, 1989). 
Studies have also found that oxidative stress, a mechanism of severe asthma, has been associated 
with exposures to the previously identified pollutants (Esposito et al., 2014; Holmstrup et al., 
2010; Suhaimi & Jalaludin, 2014) Pollutants can cause oxidative stress on the lungs, and the 
inability of antioxidant defenses to handle this increased level of oxidative stress after exposure 
is a major determinant of risk for adverse effects (MacIntyre et al., 2014).The findings of these 
studies highlight the association between pollutants and exacerbations, but the biological 
mechanisms that pollutants initiate are not fully understood, and are still under investigation.  
The United Kingdom's Committee on the Medical Effects of Air Pollutants identified 
four main mechanisms as a part of a framework for understanding how air pollution contributes 
to the exacerbation of asthma. They are: 1) oxidative stress and damage, 2) airway remodeling; 
3) inflammatory pathways and immunological responses, and 4) enhancement of respiratory 
sensitivity.(Crapo, 2003) Additionally, genetic variation, which, in part, regulate these 
mechanisms, may play a role in increasing an individual's susceptibility to asthma exacerbations 
related to air pollution exposure (McCunney, 2005).  
Certain enzyme genes such as GSTM1, GSTP1, glutathione, and S-transferase, can 
modify an individual’s risk of responses during increased levels of oxidative stress (Li et al., 
2013; Polosukhin et al., 2014). Immune response pathways are also affected by oxidizing 
pollutants, thus playing a role in the severity of asthma symptoms (Trejo Bittar, Yousem, & 
Wenzel, 2014).  Ambient hydrocarbons and diesel-exhaust particulates significantly affect the 
epigenetic mechanisms of T-cell (Treg) functions (Gruzieva, Merid, & Melén, 2014; Hew et al., 
 4 
2015). Chronic exposure to hydrocarbons or diesel-exhaust particles also leads to the suppression 
of Treg functionality and increases asthma severity when assessed by lung function testing 
(Gruzieva et al., 2014). In vitro studies with lab rats have also suggested that allergic 
inflammation is a result of PM exposure (Saravia et al., 2014). 
There is also evidence of pollution exposure effects on inhaled allergen responses in lung 
function and inflammatory responses to nitrogen dioxide, sulfur dioxide, and diesel-exhaust 
(Auerbach & Hernandez, 2012; Ezratty et al., 2014; Kodgule & Salvi, 2012). Studies have 
suggested that different mechanistic pathways may increase the effect of pollutant exposure by 
increasing the deposition of allergens in the airways when the allergens are carried into the 
airways by particles, thus increasing epithelial permeability because of oxidative injury 
(Bernstein, 2012). In conclusion, air pollutants such as PM2.5, which may cause inflammation 
and lung remodeling, may lead to oxidative injury to the airways. These effects are more severe 
in individuals that may be genetically predisposed to inflammation, making them more 
susceptible to developing clinical asthma. It is important to note that the combination of atopy 
and air pollutants may increase the risks associated to inflammatory responses when allergens 
are inhaled by individuals with asthma (Kaji et al., 2014). 
2.2 PARTICULATE MATTER (PM) 
Particulate matter (PM) is a multifaceted mixture of small particles and liquid drops made 
up of “acids such as nitrates and sulfates, organic chemicals, metals, and solid or dust particles”. 
(United States Environmental Protection Agency, 2013) A particle’s size is directly linked to its 
potential capacity to cause adverse health problems.  Particulate matter is described by its 
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aerodynamic equivalent diameter or AED. In research, particles are subdivided into AED 
categories based on how the particles are created and where they deposit in human airways: <10 
µg/m3 (PM10) or course particles, <2.5 µg/m3 (PM2.5) or fine particles, and <0.1 µg/m3 (PM0.1) or 
ultrafine particles. Particulate matter is produced through both manmade (combustion in 
mechanical and industrial processes, vehicle emissions, and tobacco smoke) and natural sources 
(volcanoes, fires, dust storms, and aerosolized sea salt), and is a complex mixture of small 
particles and liquid droplets made up of acids, organic chemicals, metals, and soil or dust 
particles (J. O. Anderson, Thundiyil, & Stolbach, 2012). 
The first major research based regulatory effort directed at setting limits on emissions and 
air pollution in the United States was the 1970 Clean Air Act (CAA), which defined the National 
Ambient Air Quality Standards (NAAQS) that set limits on six primary pollutants found in air: 
carbon monoxide, lead, nitrogen dioxide, ozone, sulfur dioxide, and particulate matter (Belden, 
2001). The World Health Organization (WHO) estimates that exposure to PM2.5 concentration 
particulates contribute to approximately 800,000 premature deaths per year, ranking it as the 13th 
leading cause of mortality worldwide (J. O. Anderson et al., 2012). 
Until the early 1990’s there was much disagreement on the type of exposures that 
affected population health. Novel studies by researchers at Utah Valley, Harvard University, and 
the American Cancer Society (ACS) set the stage with intervention and cohort studies that 
presented evidence depicting the negative health impacts such as reduced life expectancy of 
chronic exposure to particulate matter (Pope III, 1991; Pope III et al., 2002). These studies 
measured hospitalizations related to respiratory events, lung function testing, use of 
bronchodilators, and premature mortality.  The results of these studies promulgated the 
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reevaluation of the health effects of particulate matter, and prompted the review of international 
standards of air quality guidelines.  
In the United States, the U.S. Environmental Protection Agency (EPA) issued standards 
for fine particles after the evaluation of many health studies and an extensive review process 
(United States  Environmental Protection Agency, 2013). The organization established the 1997 
annual standard at a level of “15 micrograms per cubic meter (µg/m3), based on the 3-year 
average of annual mean PM2.5 concentrations.” The 24-hour standard for that same year was 
“established as a level of 65 µg/m3, determined by the 3-year average of the annual 98th 
percentile concentrations.” In September of 2006 the Environmental Protection Agency 
reevaluated the standards and the “EPA strengthened the 24-hour fine particle standard from the 
1997 level of 65 µg/m3 to 35µg/m3, and retained the annual fine particle standard at 15µg/m3.” 
(United States  Environmental Protection Agency, 2013) However, these standards are lower 
than those established by the World Health Organization (WHO), who is a leader in setting the 
norms and health standards at the international level. The most current WHO standard was set in 
2006 for PM2.5 of 25 µg/m3 for the 24-hour average and 10 µg/m3 for the annual average (World 
Health Organization Regional Office for Europe, 2006). 
Evidence supports that long-term exposure to PM2.5 leads to negative health outcomes, 
and also establishes long-term particulate exposure as a cause of cardiovascular mortality and 
morbidity. Further research is necessary to better understand the biological mechanisms of both 
short and long term impacts of PM2.5 exposure.  Although there is minimal evidence indicating 
that one specific property of PM is responsible for negative health outcomes, epidemiological 
studies have demonstrated that three different components of particulate matter, black carbon, 
secondary organic and secondary inorganic and aerosols, all significantly contribute to adverse 
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health effects as noted by the literature (Mauderly & Chow, 2008). A majority of evidence found 
that particulate matter from carbon material from traffic has a major impact on health outcomes 
in cities similar to Pittsburgh, PA. Some studies suggest that road dust, including road, brake, 
and tire wear generated by traffic contribute to negative health effects (Amato et al., 2014). 
Additionally, studies have found evidence relating biomass combustion from oil and coal 
industries to cardiovascular hospital admissions and respiratory episodes (Faustini, Héroux, & 
Forastiere, 2014).  
There is also strong evidence linking short- and long-term exposure to PM2.5 to mortality 
and morbidity events. Experimental studies have found that exposure to particulate matter results 
in airway remodeling, oxidative stress, and airway hyper-responsiveness when coupled with 
allergic sensitization, or through independent exposure of only PM when researchers adjusted for 
co-exposures (Dominici, Greenstone, & Sunstein, 2014). In terms of short-term exposure to 
ambient PM2.5, prospective cohort studies of asthmatic children and adults have found 
associations with asthma symptoms, especially in the younger cohorts (Jedrychowski et al., 
2007; Mirowsky et al., 2013). Long-term exposure to particulate matter has been associated with 
poor levels of asthma control in addition to lung function decrements in children and adults 
(Patel, Chillrud, Deepti, Ross, & Kinney, 2013). It is important to note that effects of long-term 
exposure are more detrimental to health outcomes, and lead not only to exacerbations, but also 
may be a contributing factor to the development of underlying diseases.   
More recent studies provide further evidence for associations between long-term 
exposure to PM2.5 and respiratory symptoms and asthma development. For example, a number of 
nationwide studies that used data from the National Health Interview Survey reported 
associations between long-term exposure to PM2.5 and respiratory symptoms among children and 
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adults in terms of respiratory allergy events and frequent ear infections (Bhattacharyya & 
Shapiro, 2010; Parker, Akinbami, & Woodruff, 2009). A 2010 study observed associations 
between annual average concentrations of PM2.5 and frequent asthma symptoms when they 
examined long-term exposure to PM2.5 and weekly asthma symptoms among participants (Meng 
et al., 2010). A 2012 community intervention study found a decrease in ambient PM2.5 
concentration was associated with decreases in wheezing and respiratory infections such as 
colds, bronchitis, influenza, and throat infections, suggesting that decreases in concentrations are 
beneficial to health outcomes (Noonan, Ward, Navidi, & Sheppard, 2012). Pulmonary diseases 
have been associated with exposure to higher levels of particulate matter in air pollution and 
have found decreased lung function in both children and adults, inhibited lung development in 
children, and evidence of causation that greater exposure results in increased hospitalization. 
(Nishimura et al., 2013; Weiss, Gergen, & Wagener, 1993) 
Although a number of the studies highlighted have identified associations between the 
prevalence of asthma to increased exposure to outdoor particulate matter, this finding is not 
always constant (Gowers et al., 2012). Moreover, these associations may be confounded when 
PM is correlated with nitrogen dioxide, sulfur dioxide, and ozone levels. In summary, there is 
substantial evidence that supports the idea that ambient levels of PM contribute to oxidative 
stress and allergic inflammation, thus exacerbating asthma levels.  
2.3 TRAFFIC DENSITY AND RESPIRATORY EFFECTS 
Traffic-related air pollution is a gaseous mixture that consists of combinations of 
elemental or black carbon; road dust, tire wear, and break wear known as non-combustion 
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sources; and nitrogen oxides, which are categorized as primary gaseous emissions. These 
emissions generate secondary pollutants such as nitrates, ozone, and organic aerosol. In recent 
years, modeling of airway mechanisms and exposure pathways has increased researcher’s 
understanding of the role of air pollutants in asthma exacerbations and other disease mechanisms 
(Laumbach & Kipen, 2012). Reviews from the last five years have investigated the distance from 
roadways where increased air pollution levels are observed (De Nazelle et al., 2011). In large 
metropolises such as the City of Pittsburgh, 30-45% of individuals live within 300-500m 
distance of major highways and roadways (Hazenkamp-von Arx et al., 2011). 
Numerous epidemiological studies of traffic-related air pollution have found increases in 
respiratory symptoms, negative changes in lung function results, and increased healthcare use in 
children and adults (Chang et al., 2009; Jerrett et al., 2008; Rosenlund et al., 2009; Spira-Cohen, 
Chen, Kendall, Lall, & Thurston, 2011). Studies have also found dose-response associations 
between asthma symptoms and exposure to truck traffic (H. R. Anderson, Favarato, & Atkinson, 
2013; Asher et al., 2010; Kelly & Fussell, 2011), and that short-term exposure to PM2.5, NO2, 
and CO leads to increased long term health effects (Delfino et al., 2014). Associations between 
the reduction of traffic related air pollution and reductions in asthma exacerbation in urban areas 
suggest the feasibility of decreasing symptomology in individuals with asthma by limiting 
pollution levels (Boogaard et al., 2012). In terms of lung function, research suggest that 1) long-
term exposure is associated with changes in lung function in adolescent and adults; 2) lung 
function measures are lower in people who live in more polluted areas; and 3) changing 
residences to a less-polluted area is associated with improvements in lung function (Downs et al., 
2007). This increasing body of evidence and knowledge supports the role of traffic-related air 
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pollution in exacerbating asthma in both adults and children, and suggests the need for further 
research assessing the effects of these exposures. 
2.4 RISK MODIFIERS 
Individuals with asthma, especially young children, are very susceptible to the negative 
health effects of air pollution because they are still in the process of developing their lungs and 
metabolic pathways. Additionally, they are more likely to spend increased amounts of time 
outdoors, increasing their overall levels of exposure to air pollution (Pinkerton & Joad, 2006; 
Urman et al., 2013). In utero exposure may also contribute to narrow airway development, 
another risk factor of air pollution exposure at an early age (Schildcrout et al., 2006). In terms of 
sex, asthma exacerbation levels are higher in young boys, and in adults, asthma has a higher 
prevalence in woman when compared to men (Singh & Busse, 2006). Additionally, older adults 
are more likely to be at risk for negative health outcomes related to asthma and air pollution.  
 There is minimal evidence supporting the differences in susceptibility to asthma and air 
pollution interactions related to ethnicity, but higher rates of asthma have been associated to air 
pollution in larger and more diverse US cities (Thakur et al., 2013). However, it is important to 
keep in mind that the difference in effects between different ethnicities may be associated to the 
low socioeconomic status of individuals in these cities (Thakur et al., 2013). Children living in 
families within low socioeconomic status areas are more likely to be exposed and affected by air 
pollution, making them more susceptible to asthma exacerbations (E. Chen et al., 2011; Pittman 
et al., 2012; Tzivian, 2011). Additionally, factors such as crime rates, food deserts, stress, and 
diet may contribute to overall susceptibility for individuals both young and old (McConnell et 
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al., 2010). Poor diets may make individuals more susceptible to the effects of pollutants. This is 
backed by evidence indicating higher levels of intake of fruits and vegetables are beneficial for 
strengthening oxidative stress pathways (Giles et al., 2011; Jarjour et al., 2012; Kozyrskyj, 
Bahreinian, & Azad, 2011).  Obesity has also been found to increase an individual’s 
susceptibility to the adverse effects of air pollution (Camargo, Weiss, Zhang, Willett, & Speizer, 
1999; Y. Chen, Dales, Tang, & Krewski, 2002; Ford, 2005). Secondhand smoke is also 
considered to be a modifier of the effects of air pollutants, because it contains a mixture of gasses 
and particulate matter that adversely affect asthma outcomes (U.S. Department of Health and 
Human Services, 2004; Von Mutius, 2009). 
2.5 MITIGATING IMPACT 
A technique that local governments and state health agencies may use to reduce 
particulate matter exposure for individuals living in large cities with high levels of traffic-related 
air pollution such as Pittsburgh is to issue alerts for high levels of PM2.5 levels, so that citizens 
can limit their outdoor exposures. According to the United States Environmental Protection 
Agency (EPA), individuals exposed to PM2.5 ranging from >15 - 40 µg/m3 are likely to 
experience respiratory symptoms. Localities may also prioritize making air quality data available 
to the general public on a daily basis through resources such as AirNow, a government funded 
website that reports daily air quality index levels for specific areas. Currently, minimal data is 
available on the effects of advising and educating individuals to avoid outdoor physical activity 
on days where PM2.5 levels are high. However, there is some evidence that suggests individuals 
that are more susceptible to air pollution are likely to benefit from staying indoors if they have 
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the proper resources available to them to ensure cleaner indoor air quality levels, as indoor air 
pollution may be higher (Behndig et al., 2006; Carls, 2010; McCreanor et al., 2007; World 
Health Organization, 2003). 
Individuals that are unusually sensitive to air pollution, such as those with asthma, 
chronic bronchitis, and emphysema will experience possible aggravation of heart and lung 
disease, especially those with cardiopulmonary disease, and older adults. Additionally, the EPA 
recommends that individuals that are unusually sensitive should consider reducing prolonged or 
heavy exertion related to physical activity (Mintz, 2006). Increased physical activity increases 
the amount of particulate matter inhaled per minute, thus increasing the overall total inhaled dose 
for patients. Clinicians should consider advising patients to avoid physical activity on days where 
air quality is lower as a part of their patients’ individualized asthma management plans.  
 The EPA also recommends that individuals with asthma should live at least 300-meters 
from major roadways, particularly in areas that are more likely to have heavy truck exposure or 
higher levels of ozone exposure (Mintz, 2006). Another technique to reduce exposure may be to 
close windows when traveling roads with heavy traffic and during rush hour (Yang et al., 2015). 
Lastly, inhaled corticosteroid therapy, in conjunction with behavioral efforts to reduce exposure 
to PM, may decrease inflammatory responses to pollutants (Croisant & Scott, 2014; Rodrigo, 
2014). 
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3.0  METHODOLOGY 
3.1 SURVEY 
This thesis is based on a survey developed for the recruitment of research participants at 
the Asthma Institute at the University of Pittsburgh Medical Center (UPMC). (Appendix B) The 
baseline registry questionnaire was approved by the IRB on January 16, 2014 and consists of 
demographic information, medical history, childhood and family history, asthma triggers, past 
and current medication usage questions, and on-site lung function test results recorded at the 
Asthma Institute at the University of Pittsburgh Medical Center. Lung function tests, also known 
as spirometry or pulmonary function tests (PFTs) assess how well an individual’s lungs work by 
determining how much air the lungs can hold, and how quickly air can move in and out of the 
lungs. They also measure how well the lungs put oxygen into and remove carbon dioxide from 
the lungs. For the purpose of this study, forced vital capacity (FVC), forced expiratory volume 
(FEV1), and the ratio of forced vital capacity to forced expiratory volume (FEV1/FVC) were 
used. FVC measures the amount of air an individual can exhale with force after he inhales as 
deeply as possible, FEV1 measures the amount of air an individual can exhale with the force of 
one breath at one second, and FEV1/FVC measures the percentage of the vital capacity which is 
expired in the first second of maximal expiration. In patients with obstructive lung disease, 
FEV1/FVC is lower than 70% and can be as low as 20-30% in severe obstructive airway disease. 
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3.2 EXPOSURE ASSIGNMENT 
The coordinate locations of residential addresses from the Asthma Registry were cleaned 
and standardized (Figure 1) and then geocoded in ArcGIS® using an address locator specifying 
StreetMap Premium™ reference data (Figure 2). The match rate was 97.6 % for a total of 453 
addresses. One additional survey participant was excluded because of missing pulmonary 
function tests, making the final study sample (n = 452). 
 
Figure 1: Exclusion Cleaning Methods for Asthma Registry Case Data and Geocoding Methodology 
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Figure 2: Asthma Registry Geocoded Addresses 
3.3 PM2.5 
A predicted surface of PM2.5 was developed for the six county area surrounding the city 
of Pittsburgh using a Land Use Regression (LUR) model. This model was modified from one 
previously developed for a smaller area of Allegheny County (Tunno et al., 2015) (in press). 
Significant covariates in the LUR model were PM2.5 emissions aggregated from the U.S. 
Environmental Protection Agency’s (USEPA) 2011 National Emissions Inventory (NEI) and 
signaled intersections within a 750-meter buffer. Near-residence PM2.5 exposures were assigned 
by averaging the concentrations within a 300-meter buffer around each residential location. 
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Exposure estimates were then temporally adjusted using daily data monitoring data from the 
USEPA Air Quality System (AQS) site in Lawrenceville, PA to obtain exposure for a one month 
period prior to the month of the lung function test. 
3.4 TRAFFIC DENSITY 
Traffic data were obtained from the Pennsylvania Department of Transportation, which 
uses raw traffic counts to calculate statewide traffic volumes along roadway sections. Data 
includes 2014 annual average daily traffic (AADT) and annual average daily truck traffic 
(ADTT) for primary and secondary roadways within the study domain.  
 An interpolated surface of traffic volume (AADT) was derived using a kernel density 
function in ArcGIS. Kernel density calculates the density of roadways (primary and secondary 
roads) in the neighborhood of each output raster cell. Conceptually, a smoothed curved surface is 
fitted over each line feature by applying a Gaussian decay function to traffic volumes on road 
segments within the study domain. Values are greatest on the line feature and diminish with 
distance from the road. From this traffic density surface, we calculated mean traffic density 
within a 100 meter buffer and 300 meter buffer of each residential location. 
3.5 DATA ANALYSIS 
A total of 452 valid responses were used for the analysis of this study. Valid responses 
were defined as completing on-site spirometry results, and providing a current address that was 
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able to be geocoded. The data were analyzed with the statistical program STATA 13 after being 
entered into a Stata worksheet and cleaned for missing values. We used linear regression analysis 
to determine: A) the linear relationship between exposures and lung function tests; and B) to 
determine the association between exposures with road density exposures and their respective 
quartiles. We adjusted for race, age, and sex as confounders.  
 
 18 
4.0  RESULTS 
The mean age of respondents was 41.13 (age, 18-82) years of age. 65.49% of participants 
identified as female, and 87.61% of respondents identified as White (Table 1).  According to 
Body Mass Index, determined by height and weight recordings during the day of the on-site PFT, 
29.65% of respondents were overweight, while 41.81% were obese.   
Table 1: Demographic Data 
Characteristic Overall (n= 452) 
Age (years as a whole number) a 41.13±15.80 
Height (in.) a 66.82±8.46 
Sex b   
    Female 296 (65.49) 
    Male 152 (33.63) 
    Unidentified  4 (0.88) 
Race b  
   White 396 (87.61) 
   Black 47 (10.40) 
   Asian 3 (0.66) 
   Native 1 (0.22) 
   Other 5 (1.11) 
Weight Category bc  
   Underweight 5 (1.11) 
   Normal 124 (27.43) 
   Overweight 134 (29.65) 
   Obese 189 (41.81) 
Urban/Suburban 352 (77.88) 
Rural 100 (22.12) 
PFT a  
   FEV1 2.72 ± 0.95 
   FEVPCT 82.66 ± 19.83 
   FVC 3.63 ± 1.16 
   FVCPCT 89.33 ± 18.33 
   Ratio 00.75 ± 00.17 
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Abbreviations: PFT = Pulmonary Function Tests; FEV1 = Forced Expiratory Volume; FEVPCT = Percent of Forced Expiratory 
Volume; FVC = Forced Vital Capacity; FVCPCT = Percent of Forced Vital Capacity; Ratio = Ratio of FEV1 over FVC 
a Mean ± standard deviation 
b Number of subjects (%) 
c Weight classifications are determined by Centers for Disease Control and Prevention guidelines for weights (ADD definitions) 
Out of the 452 individuals that completed the survey, 180 respondents were diagnosed 
with asthma in childhood (before the age of 18), whereas 272 individuals were diagnosed with 
asthma in adulthood (on or after the age of 18). Of the number of individuals that responded to 
their insurance status (235 responses), 53 (22.5%) use Medicare or Medicaid, 155 (65.9%) have 
private insurance, and 27 (11.6%) self-pay for their medical expenses. Of the individuals that 
responded to questions about their smoking history (447 responses), 344 (76.9%) respondents 
had never smoked, 99 (22.1%) indicated they had smoked at some point in their lives, and 4 
(1.1%) respondents indicted having smoked “in moderation: through the course of their 
lifetimes”. 270 (60.6%) individuals indicated that they have ever had an asthma- related ER visit, 
165 (37.2%) said they had an asthma related overnight hospital stay, and 57 (12.8%) respondents 
stated that they have had a asthma related ICU admission (Table 2). 
Table 2: Clinical Data 
Characteristic Overall (n=452) 
Age of Asthma Onset 
   Early 180 
   Late 272 
Insurance (n= 235) 
   Medicare/Medicaid 53 
   Private  155 
   Self-Pay 27 
Ever-Smoked (n=447) 
   No 344 
   Yes 99 
   In Moderation 4 
Asthma Related ER Visits (n=445) 
   No 175 
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   Yes 270 
Asthma Related Overnight Hospital Stay (n=443) 
  No 278 
  Yes 165 
Asthma Related ICU Admissions (n=442) 
   No 385 
   Yes 57 
Symptoms 
   Coughing (n=446) 
      Never 78 
   Yes/Currently 131 
      Past Only 237 
   Sputum (n= 445) 
      Never 56 
      Yes/Currently 152 
      Past Only 237 
   Chest Tightness (n=444) 
      Never 36 
      Yes/Currently 178 
      Past Only 230 
   Wheezing (n=445) 
      Never 30 
     Yes/Currently 194 
      Past Only 221 
   Shortness of Breath (n=445) 
      Never 22 
      Yes/Currently 227 
      Past Only 196 
   Nighttime Symptoms (n=445) 
      Never  106 
      Yes/Currently 170 
      Past Only 169 
Asthma Control Medication Use 
   Inhaled steroids (n=445) 
 No 169 
       Yes 276 
   Inhaler beta-agonist (n= 445) 
      Never 15 
      Yes/Currently 340 
      Past Only 90 
   Nebulized beta-agonist (n= 443) 
      Never 180 
      Yes/Currently 81 
      Past Only 182 
   Oral beta-agonist (n= 437) 
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Table 2 Continued
      Never 421 
      Yes/Currently 3 
      Past Only 13 
   Long-acting bronchodilator (n= 444) 
      Never 174 
      Yes/Currently 145 
      Past Only 125 
   Leukotriene inhibitor (n= 443) 
      Never 219 
      Yes/Currently 116 
      Past Only 118 
   Theophyllines (n= 443) 
      Never 364 
      Yes/Currently 13 
      Past Only 66 
   Ipratroprium bromide (n=441) 
      Never 352 
      Yes/Currently 17 
      Past Only 12 
   Tiotroprium bromide Spiriva (n=440) 
      Never 398 
      Yes/Currently 10 
      Past Only 32 
   Injectable Corticosteroids (n=443) 
      Never 382 
      Yes/Currently 10 
      Past Only 51 
a Early Asthma Onset = Before the age of 18; Late Asthma Onset = After the age of 18 
Current asthma symptoms in respondents included: Coughing 131 (30.9%), sputum 152 
(34.2%) chest tightness 178 (40.1%), wheezing 194 (43.6%), shortness of breath 227 (51%), and 
nighttime symptoms 170 (38.2%). Current asthma control medication use in respondents 
included: Inhaled steroids 276 (62.0%), inhaler beta-agonist 340 (76.4%), nebulized beta-agonist 
81(18.3%), oral beta agonist 3 (<1%), long acting bronchodilator dilator 145 (32.7%), 
theophyllines 13 (<5%), ipratroprium bromide 17 (<5%), trioprium bromide 10 (<5)%), and 
injectable corticosteroids 10 (<5%). (Table 2) 
22 
Table 2 Continued
Air pollution (PM2.5) and pulmonary function test data are presented in Table 1 and Table 
3 by overall values. Overall PM2.5 levels ranged between 6.39 and 21.59 µg/m3 (IQR= 3.59); 
FEV1 levels ranged from 0.7 to 5.4 liters/second (IQR= 1.3); FEV1PCT levels ranged from 28% 
to 139% (IQR = 25.5); FVC levels ranged from .4 to 7.4 liters (IQR= 1.5); FVCPCT levels 
ranged from 1% to 136% (IQR= 24); Ratio levels ranged from 35% to 325% (IQR) = 13%.   
 Pulmonary function tests showed associations with traffic-related pollutants. A linear 
regression analysis was conducted after checking for assumptions of linear regression: 1) 
variables were normally distributed, and 2) a scatter plot showed a linear relationship between 
the independent and dependent variables. The researcher conducted a crude analysis for the 
relationship between PFT test results and PM2.5 and road density exposure at the 100-meter and 
300-meter levels. A significant association was found between Road 300 meter exposure levels 
and FEV1 test results F (3, 448) = 2.41 p < .05; and Road 300 meter exposure levels and FEV1 
PCT test results F (3, 448) = 2.02 p < .05 (Figure 3) (Figure 4). No crude associations were 
found between PM2.5 and FEV1, FEV1PCT, FVC, FVC PCT, FEV/FVC. (Table 3) No crude 
associations were found between FVC, FVC PCT, FEV/FVC and the Road 100 meter and Road 
300 meter exposures (Table 4). When adjusting for the confounders of race, age, and sex, there 
was no true association found between the PFT test results and road density or PM2.5 exposure 
(Table 5). 
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Figure 3: Boxplot of FEV1 and Quartiles of 300-meter Traffic Density Values 
 
Figure 4: Confidence Interval for the Linear Regression Model of FEV1 and 300-meter Traffic Density 
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 Table 3: Linear Regression Analysis of PM2.5 Exposure and Pulmonary Function Test Results 
 PM2.5 β (std. error) Confidence Interval P>|t| 
FEV -.0145765 (.0158257) (-.045678, .0165249) 0.358 
FEV PCT -.4632595 (.3309891) (-1.113736, .1872167) 0.162     
FVC PCT -.0706959 (.306632)  (-.6733043, .5319125) 0.818     
Ratio -.002065 (.0028271)  (-.007621, .003491) 0.466      
 
Table 4: Linear Regression Analysis of 100-meter and 300-meter Road Density Exposures and Pulmonary 
Function Tests by Quartile Distribution (Excluding Confounders) 
 Road 100-meter 
   
Confidence Interval P>|t| Road 300-meter 
   
Confidence Interval P>|t| 
FEV       
     Q1 - - - - - - 
     Q2 .1699115 (.1260998)  (-.077909, .417732) 0.179      .0663717 (.1253911) (-.1800561, .3127994) 0.597     
     Q3 .0814159 (.1260998) (-.1664046, .3292364) 0.519     .0973451 (.1253911)  (-.1490826, .3437729) 0.438     
     Q4 .1415929 (.1260998) (-.1062276, .3894134) 0.262     .3176991 (.1253911) (.0712714, .5641268) 0.012*  
FEV PCT       
     Q1 - - - - - - 
     Q2 -1.017699 (2.646083) (-6.217976, 4.182578) 0.701     4.672566 (2.629176) (-.4944826, 9.839615) 0.076     
     Q3 -.6725664 (2.646083) (-5.872843, 4.527711) 0.799     2.699115 (2.629176) (-2.467934, 7.866164) 0.305 
     Q4 -1.274336 (2.646083) (-6.474613, 3.925941) 0.630 6.088496 (2.629176) (.9214466, 11.25554) 0.021* 
FVC       
     Q1 - - - - - - 
     Q2 .219469 (.1547044)  (-.0845674, .5235054) 0.157     .0469027 (.1543571)  (-.2564513, .3502566) 0.761     
     Q3 .1389381 (.1547044) (-.1650983, .4429744) 0.370     .1654867 (.1543571) (-.1378672, .4688407) 0.284     
     Q4 .1982301 (.1547044) (-.1058063, .5022665) 0.201     .2982301 (.1543571) (-.0051239, .6015841) 0.054     
FVC PCT       
     Q1 - - - - - - 
     Q2 -1.415044 (2.444923) (-6.219986, 3.389898) 0.563      4.146018 (2.433786)  (-.6370369, 8.929072) 0.089     
     Q3 -1.729204 (2.444923) (-6.534146, 3.075738) 0.480 4.516814 (2.433786) (-.2662404, 9.299869) 0.064     
     Q4 -1.839823 (2.444923) (-6.644765, 2.965119) 0.452 4.420354 (2.433786) (-.3627006, 9.203409) 0.070     
Ratio       
     Q1 - - - - - - 
     Q2 .0159292 (.0225435) (-.028375, .0602334) 0.480 -.0004425 (.0225049) (-.0446708, .0437858) 0.984 
     Q3 -.0048673 (.0225435) (-.0491715, .039437) 0.829 -.0234513 (.0225049) (-.0676796, .020777) 0.298 
     Q4 -.0048673 (.0225435) (-.0491715, .039437) 0.829 .0127434 (.022504) (-.0314849, .0569716) 0.572 
*p<0.05 
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 Table 5: Regression Analysis of 100-meter and 300-meter Road Density Exposures and Pulmonary Function 
Tests by Quartile Distribution (Including Confounders of Race, Age, and Sex) 
 
 
Road 100-meter 
   
Confidence Interval P>|t| Overall 
P>|t| 
Road 300-meter 
   
Confidence Interval P>|t| Overall 
P>|t| 
FEV    0.753     
     Q1        0.173 
     Q2 -.0082454 (.0928399) -(.1907172, .1742263) 0.929       .1011537 (.091122) (-.0779427, .2802501) 0.268   
     Q3 -.06301 (.093811) (-.2473905, .1213705) 0.502      .0308091 (.0942028) (-.1543413, .2159594) 0.744  
     Q4 -.0952707 (.1032438) (-.2981908, .1076494) 0.357   .200639 (.1012842) (.0015705, .3997074) 0.048  
FEV PCT         
     Q1    0.791     
     Q2 -1.373221 (2.607455) (-6.49803, 3.751588) 0.599  3.311116 (2.559223)  (-1.718896, 8.341128) 0.196    0.253 
     Q3 -1.235306 (2.63473) (-6.413722, 3.94311) 0.639  1.567969 (2.645731) (-3.632071, 6.768009) 0.554  
     Q4 -2.937422 (2.899654) (-8.636533, 2.761688) 0.312  5.262655 (2.844615) (-.3282805, 10.85359) 0.065  
FVC         
     Q1    0.899    0.475 
     Q2 -.0427108  (.1102037) (-.2593101, .1738885) 0.699  .1355738 (.1081652) (-.0770189, .3481665) 0.211      
     Q3 -.0679324 (.1113565) (-.2867974, .1509326) 0.542  .1069225 (.1118215) (-.1128564, .3267014) 0.340      
     Q4 -.0881605 (.1225535) (-.3290326, .1527116) 0.472  .176231 (.1202273) (-.0600691, .4125311) 0.143      
FVC PCT         
     Q1    0.669    0.364 
     Q2 -2.325126 (2.385461) (-7.013619, 2.363367) 0.330  3.230949 (2.341336) (-1.370818, 7.832716) 0.168  
     Q3  -2.346879 (2.410414) (-7.084416, 2.390658) 0.331      3.75034 (2.420479 (-1.006979, 8.507659) 0.122      
     Q4 -2.998181 (2.652783) (-8.212081, 2.215719) 0.259     3.871713 (2.602431) (-1.243221, 8.986648) 0.138      
Ratio         
     Q1        0.75 
     Q2 .0228858 (.0232932) (-.0228958, .0686674) 0.326 0.522 -.0044025 (.022862) (-.0493372, .0405322) 0.847  
     Q3 -.0019461 (.0235369) (-.0482066, .0443144) 0.934    -.0289919 (.023635) (-.0754455, 0174618) 0.221  
     Q4 -.010794 (.0259035) (061706, .040118) 0.677  .0050388 (.0254119) (-.0449068, .0549844) 0.843  
*p<0.05 
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5.0  DISCUSSION 
This pilot study presents the first analysis of pollution exposure rates and asthma 
exacerbation data specific to residents living in Alleghany County, PA (Pittsburgh, PA). The 
main goals of this study were to document the respiratory health impact of road density levels 
and particulate matter specific to city residents to help guide future research and policy. This 
study also provided a unique opportunity to assess the effectiveness of data collection strategies 
related to air-pollution exposure when using the data to analyze individual specific medical 
outcomes, such as asthma exacerbation rates. The results indicate significant associations 
between forced expiratory volume test results (FEV1) and the highest quartile mean 300-meter 
traffic density of each residential location. As highlighted in previous sections, forced expiratory 
volume flow is the volume of air expired in the first second during maximal expiratory effort. 
FEV1 levels are generally lower in patients that have both obstructive lung disease because of 
airway resistance, and restrictive lung disease because of low vital capacity. It is important to 
note that researchers have previously reported significant associations between increased 
concentrations of a number of pollutants, specifically reductions in FEV1. (Li et al, 2011) 
The lack of statistical significance in the associations of other main models in the current 
analysis may be due to several factors. The environmental exposure data collected for this study 
provided a brief snapshot in space and time of a potential exposure-response relationship. It is 
possible that the pollutant exposure levels and variability occurring during this study period were 
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not sufficient to produce a statistically detectable response in a clinical testing atmosphere. 
Moreover, single measurements of lung function tests provide only a snapshot of asthma severity 
at the time they were recorded, and air pollution data for the purpose of this study was collected 
during the month prior to the date of lung function testing. These results may attest to a number 
of factors, including baseline differences in modifying risk factors among the different 
respondents, as well as limited power to detect subtle changes in daily air quality exposure 
levels.   
Limitations of this study exist related to the analytical methods. First, because this is a 
cross-sectional study, we cannot assume any form of causation. Additionally, exposures to PM 
and traffic density are roughly estimated through GIS, which may contain errors, and there are 
no indoor exposure readings available for those that do have exacerbated asthma symptoms. 
Furthermore, although the study sample size (N = 452) was large enough to detect for the 
expected effects, this study was conducted through the use of a convenience sample that is not 
truly demographically representative of the Allegheny county population. This sampling strategy 
further confounds the results of this study. Because race and socioeconomic status have shown to 
play a significant role in asthma incidence and exacerbation rates, it is likely that a randomized 
sample may have provided significant results. 87.61% of the sample identified as White and 
10.40% identified as Black; however, according to 2013 census data, 79.9% of the Allegheny 
County population identifies as White and 13.3% identifies as Black.  
The main strength of the study is that the population consisted of a well-characterized 
study population that meets rigorous testing for asthma diagnosis, unlike other epidemiologic 
studies that rely on self-referred diagnosis.  As the registry grows, the study will have power to 
detect potential effect modifiers, including use of medications, and the response to pollution 
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according to different phenotypical features (i.e. age of onset, atopy, severity level). Although 
the analysis is largely non-significant when accounting for other demographic variables, the 
univariable analysis does suggest that there is a chronic or cumulative effect of PM2.5, which is 
related to lower lung function.   
It is recommended that future research studies that focus on racially and 
socioeconomically diverse cities such as Pittsburgh consider the representativeness of their study 
population to the target area. It is important to note, however, that in the clinical setting, 
collecting data of this caliber may be limited in scope because of the demographic populations 
that are most likely to seek care and treatment at institutions that do have the ability to conduct 
research studies such as the one presented in this paper.  Subsequent studies need to be done in 
this regional area, using better exposure resolution, to determine more accurately the chronic 
effects of air pollution on the lung function of asthmatics. Eventually, this line of research could 
lead to preventive strategies to prevent loss of function and improve quality of life among more 
susceptible asthmatics exposed to higher ambient pollution concentrations.  
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APPENDIX: IRB APPROVED REGISTRY 
PEMC 
 
 
Date Completed Assessor 
ID# 
Subject ID# 
               
 
Asthma & Allergic Diseases Registry Questionnaire 
Date of Consent:  __ __/__ __/__ __ __ __                     Date Blood Drawn: __ __/__ __/__ __ __ 
__       
Demographics: 
 
Date of Birth __ __/__ __/__ __ __ __              Age ____   
Contact Information (for you/your child): 
1. First Name: _________________  confname  MI: ___   conmi  Last: ___________________ 
conlname  
 
     Maiden/ Other Name(s): __________________________________________  conmdname 
 
     Address: _______________________________________________________  conaddress 
 
     City: ______________________________   concity  State: _____    constate  Zip: _________  
conzip 
 
     Phone: (H / W / C)  (     ) - _ _ _ - _ _ _ _   conphone1  (H / W / C)(     ) - _ _ _ - _ _ _ _  conphone2 
                      conphonetype1                                                                    conponetype2 
     Email: _________________________________________________________  conemail 
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Secondary Contact Information 
2. Name(s): ___________________________________________________  conname2 
 
Address: ______________________________________________________  conaddress2 
 
City: _____________________________  concity2  State: _____  constate2  Zip: _________  
conzip2 
 
      Phone: (H / W / C)(     ) - _ _ _ - _ _ _ _  con2phone1 (H / W / C)(     ) - _ _ _ - _ _ _ _  con2phone2 
             con2phonetype1                                                                  con2phonetype2 
Relation: __________________________  relation 
Provider Information 
 
1.  Primary Care Provider: 
 
     Clinic Name: ___________________________________________________  primcarename 
 
     Doctor: _______________________________________________________  primcaredr 
  
     Address: ______________________________________________________   primcareaddrs 
 
     City: ________________________  primcarecity  State: _____  primcarestate  Zip: _______  
primcarezip 
 
     Phone: (     ) - _ _ _ - _ _ _ _  primcarephone      Fax: (     ) - _ _ _ - _ _ _ _  primcarefax 
 
     Email: _____________________________________________________  primcareemail 
 
 
2.  Specialist: Pulmonologist/ Allergist- Immunologist 
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     Clinic Name: ___________________________________________________  specname 
 
     Doctor: _______________________________________________________  specdr 
  
     Address: ______________________________________________________   specaddress 
 
     City: __________________________  speccity  State: _____  specstate  Zip: __________  speczip 
 
     Phone: (     ) - _ _ _ - _ _ _ _  specphone      Fax: (     ) - _ _ _ - _ _ _ _  specfax 
 
Referring Physician: 
 
1.  Chose one:  refermd    1  Family Medicine/ Internal Medicine 
 
      2  Pulmonologist/ Allergist- Immunologist 
 
2.  Do we have your permission to request pertinent medical information from 
      these providers?    permitinfo 
0  No   1  Yes    2  Both 3  One only  
oneonly   1  First      2  Second   
 
General Information About You/Your Child 
 
1.  Age:  ______   ycage 
 
2.  Sex:  gender  1  Male  2  Female 
 
3.  Race:  race  1  White/ Caucasian 
   2  Black/ African American 
   3  Asian/ Pacific 
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   4  Native American 
   5  Other ______________________________________othrace 
 
4.  Ethnicity:  ethnicity   1  Hispanic/ Latino  2  NOT Hispanic/ Latino 
 
5.  Marital Status:       1  Single, never married   maritalstats 
2  Married    
3  Remarried   
4  Separated  
5  Divorced    
6  Widowed 
 
6. Are you/your child employed outside of home?   emplyd 
1  Yes  0  No  
 
7. Occupation:  ______________________________________  occupation 
 
8. Type of Insurance:  1  Medicare/Medicaid 2  Private 3  Self-pay  insurance 
 
9. Education:  Highest level of school completed by you/your child and either parent (mother or 
father): 
    You/Your Child educself     Either parent educparent   
Less than fifth grade          
Fifth grade to eighth grade         
Junior High School (9th grade)        
Partial High School (10-11th grade)        
High School graduate          
Partial College          
Complete College          
Graduate School                                
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 10. Did you/your child miss school or work due to asthma in the past year?   asthmadays 
    1  Yes    0  No 
 
 10a. If YES, how many days of school or work were missed in the last 30 days (1 month) 
due to asthma?  ____   nodaysmiss 
 
 
 
 
Disease Onset 
 
1.  When did you first notice asthma symptoms in yourself/your child?    
Year: _____   frstasthmayr  Age: ____  frstasthmaage 
 
2.  When did a physician first diagnose you/your child as having asthma? 
Year: _____   frstdiagyr  Age: ____  frstdiagage 
Smoking History 
1.  Are you/your child exposed to Second Hand smoke during your day?  scndhandsmk 
1  Yes    0  No 
 
1a) If YES: Location (mark all that apply):   
                     Home schdhome    Work schdwork     Other schother 
 
2.  Have you/your child ever smoked cigarettes?  eversmoke 
 1  Yes (if more than 1 yr of smoking an average of 1 pack per day, or 2 years 
of  
                             ½ pack per day) 
2  If less than this, how many cigarettes a day?_____  cigsaday 
  0 No 
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3.  Do you/your child now smoke cigarettes?  cursmoke 
 1  Yes  0  No 
 
4.  How many years have you/your child smoked cigarettes:   yrssmoke 
1  < 1 year          2  1-5 years        3  <5 years     
4  5-10 years        5  10-20 years     6  more than 20 years  
5.  Average packs per day:  1  less than one   2  one     3  more than one  avgpcksday 
 
6.  Have you/your child quit smoking?         0  No    1  Yes   quitsmke 
 
                                                                       If Yes, ____years  yrsquite__  _months  mnthsquite 
Childhood History 
  Yes No Don’t know 
1.  Did your mother smoke during pregnancy? If answering for your  
     child, did you smoke during your pregnancy with your child?  
pregsmk 
1  0  888  
     
2.  Did your father, if living together with your mother, smoke in the  
     home during her pregnancy? If answering for your child, did your  
     child’s father live with you and smoke during your pregnancy?   
                                                                                                                             
fathersmk 
1  0  888  
     
3.  Were you/your child breast-fed?  breastfed 1  0  888  
 
Family History: 
  Yes No 
1.  Are you/your child adopted?  adopted 1  0  
   
2.  Do you/your child have biological Brothers / Sisters or children?  siblings 1  0  
   
                                                    If Yes: How many Brothers/Sisters? ___  siblingno  Children? ____  
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nochildren 
   
3.  Do you/your child have non-biological(step-) / adopted Brothers / Sisters or 
children?   
                                                                                                                                                          
adoptedsibs 
1  0  
   
                                                If Yes: How many Brother/Sisters? _____  adptsibno  Children? ____  
adptchldrno 
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To the best of your knowledge, has a physician ever diagnosed your/your child’s biological 
Father / Mother / Brother / Sister or Child with: 
Father Mother Brother / Sister 
or Child 
(Biological) 
Brother / Sister 
or Child 
(Adopted) 
1) Asthma?  1   Yes 
0   No 
 888  Don’t 
   Know 
fasthma 
 1   Yes 
0   No 
 888  Don’t 
     Know 
masthma 
 1   Yes 
0   No 
 888  Don’t 
     Know 
sibasthma 
1   Yes 
0   No 
 888  Don’t 
     Know 
adptsibasthma 
2) Chronic
Obstructive Lung 
Disease? Chronic 
Bronchitis / 
Emphysema? 
 1   Yes 
0   No 
 888  Don’t 
    Know 
fchrnlung 
 1   Yes 
0   No 
 888  Don’t 
     Know 
mchrnlung 
 1     Yes 
0     No 
    888  Don’t 
       Know 
sibchrnlung 
1   Yes 
0   No 
 888  Don’t 
     Know 
adptsibchrnlung 
3) Hay Fever
(Allergies)? 
 1   Yes 
0   No 
 888  Don’t 
    Know 
fhayfvr 
 1   Yes 
0   No 
 888  Don’t 
     Know 
mhayfvr
 1   Yes 
0   No 
 888  Don’t 
     Know 
sibhayfvr 
 1   Yes 
0   No 
 888  Don’t 
     Know 
adptsibhayfvr 
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Health Care Utilization for Asthma Related Illness 
Yes No 
1. Have you/your child ever had any unscheduled visits or
phone contacts related to asthma that required a boost in
your/your child’s medications?  asthmdboost
1 0 
  mdboostno            1a) If YES, number of times in the last year: 1  one 2  two or more 0  none 
2. Have you/your child ever had any emergency room visits
related to asthma?  ervisits
1 0 
  ervisitno     2a) If YES, number times in last year: 1  one 2  two or more 0  none 
3. Have you/your child ever had any overnight
hospitalizations due to asthma?  onhosp
1 0 
  onhospno           3a) If YES, number in the last year: 1  one 2  two or more 0  none 
4. Have you/your child ever been admitted to the intensive
care unit (ICU)?  admiticu
1 0 
5. Have you/your child ever had any respiratory episodes
that were life threatening (required intubation or 
associated with loss of consciousness)?  lifethreat 
1 0 
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Triggers 
Have any of the following caused you/your child to have asthma symptoms such as coughing, 
wheezing or shortness of breath?  
1. Allergens
Never 
Some of 
the time 
Most of 
the time 
All of 
the time 
Don’t 
know 
a. Cats  cats 0 1 2 3 888 
b. Dogs  dogs 0 1 2 3 888 
c. House dust  housedust 0 1 2 3 888 
d. Molds/damp areas  molds 0 1 2 3 888 
2. Irritants:
a. Sprays or perfumes  perfumes 0 1 2 3 888 
b. Tobacco smoke  smoke 0 1 2 3 888 
3. Daily Physical Activities:  phyact 0 1 2 3 888 
4. Exercise:  exercise 0 1 2 3 888 
5. Cold/upper Respiratory tract infection:  cold 0 1 2 3 888 
6. Emotional factors:
Never 
Some of 
the time 
Most of 
the time 
All of 
the time 
Don’t 
know 
a. Stress/anxiety  stress 0 1 2 3 888 
b. Anger  anger 0 1 2 3 888 
7. Drugs/Medicines
a. Aspirin, ibuprofen, Motrin,
aleve/naprosyn, etc.  aspirin 
0 1 2 3 888 
b. Penicillin  penicillin 0 1 2 3 888 
8. Women/Girls only:
a. Menstruation  menstruation 0 1 2 3 888 
b. Pregnancy  pregnancy 0 1 2 3 888 
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Seasons 
How severe are your/your child’s asthma symptoms in each of the seasons of the last year? 
None Mild Moderate Severe 
1. Spring  spring 0 1 2 3 
2. Summer  summer 0 1 2 3 
3. Fall  fall 0 1 2 3 
4. Winter  winter 0 1 2 3 
Additional Respiratory Conditions 
Do you/your child have or ever had: 
Never Currently Past only Don’t know 
1. Seasonal nasal or eye-related allergies  nasallergies 0 1 2 888 
2. Eczema (itchy, scaley, weepy skin rash without
hives)  
0 1 2 888 
3. Chronic sinusitis (sinus congestion, post nasal drip) 0 1 2 888 
4. Sinus surgery  sinusurg 0 1 2 888 
5. Acute sinusitis (episodes of sinus pain/nasal
discharge treated with antibiotics)  actsinusitis 
0 1 2 888 
Never Currently Past only Don’t know 
6. Nasal Polyps (growths or mass protruding from
mucous membrane usually associated with structural 
abnormality or obstruction of nasal passages)   
0 1 2 888 
7. Vocal Cord Dysfunction (spasm of the upper airway
throat or voice box)  
0 1 2 888 
8. Obstructive Sleep Apnea (breathing problems
during sleep that cause low oxygen levels and are
usually treated with a machine)  obsslapnea
0 1 2 888 
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9. Supplemental Oxygen   supoxygen 0 1 2 888 
10. Pneumonia diagnosed by a doctor.  penudiag 0  Never 1 Past 888  Don’t 
know 
       10a. Did you/your child get a chest x-ray?  chstxray 1  Yes 0  No 888  Don’t 
know 
       10b. Did you/your child get an antibiotic?  antibiotic 1  Yes 0  No 888  Don’t 
know 
Non-respiratory Related History 
Do you/your child have or ever had: 
Never Currently Past only Don’t know 
1. Heartburn/Gastroesophageal Reflux Disease (GERD)
 gerd 
0 1 2 888 
2. Depression  depression 0 1 2 888 
3. Anxiety/ Panic disorder  anxiety 0 1 2 888 
4. Hypertension (high blood pressure)  htn 0 1 2 888 
5. Osteoporosis (thinning or decreased strength of bones)
 osteo 
0 1 2 888 
6. Diabetes/high sugars   diabetes 0 1 2 888 
7. Cataracts  cataracts 0 1 2 888 
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Women/Girls Only ____N/A  male 
1. You/your child has started menstr/preg/menp  Menstruation  Pregnancy  Menopause 
         Age at which you/your child began menstruation:  _________  menstrage
2. Contraceptives:
 contracptv 
0  Never 1  Currently 2  Past only 888  Don’t know 
    2a) If Yes, Type:  type 1  Condom 2  Oral 3  Patch 4  Ring 5  IUD 
3. Have you/your child ever been
pregnant:  evrpregnnt
1  Yes 0  No 
    3a) If YES, During Pregnancy did you/your child’s asthma symptoms:  prgnasthma
1  Improve 2  Worsen 3  Remain Same 4  Not Applicable 
4. Surgery to remove you uterus (womb)    (If YES Date completed: __/__/___)  utersrgdt
utersrg 0  No 1  Yes 8888  Don’t know 
5. Surgery to remove one or both ovaries       (If YES Date completed: __/__/___)  ovaryremvedte 
ovaryremve 0  No 1  Yes 8888  Don’t know 
6. Hormone Replacement Therapy
 hrt 
0  Never 1  Currently 2  Past only 888  Don’t know 
7. Postmenopausal:  pstmenopause 0  No 1  Yes 2  Uncertain 
       7a) If Yes, did the onset occur: naturalonst     1  Naturally     2  Surgically 
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General Symptoms of Lung Disease 
Do you/your child have or ever had:  Yes/currently Past only Never 
1. Cough: Deep, chest, chronic  cough 1 2 0 
2. Sputum: Phlegm or mucus while coughing  sputum 1 2 0 
3. Chest tightness: difficult to breathe deeply/pressure in chest
   chesttightness 
1 2 0 
4. Wheezy, Whistling or Musical sound in Chest:  wheezy 1 2 0 
5. Shortness of Breath  shortnessbreath 1 2 0 
6. Nighttime Symptoms: waking from sleep, nighttime use of
Albuterol, early morning chest tightness  pmsymptoms
1 2 0 
Medications 
A.  Steroids Yes/currently Past only Never 
1. Do/Did you/your child take oral steroids (prednisone or
medrol) on a daily basis?  posteroids
1 2 0 
2. What is the total daily dosage?  dose 1  1-5 mg 2  6-10mg 3  11-20mg 4  21+mg 
3. How many steroid bursts did you/your
child use in the last year?  steroidbursts
1  One 2  2-3 3  4 or more   4  None 
4. Do you/your child currently use inhaled steroids?  inhldsteroids 0  No 1  Yes 
a. If Yes:  Which one(s) do you use?  (Please select only two)
    Advair Diskus (fluticasone/salmeterol)  advaird 1  100/50 2  250/50 3  500/50 
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    Advair HFA (fluticasone/salmeterol)  advairhfa 1  45/21 2  115/21    3 230/21 
    Aerospan HFA  (Flunisolide hemihydrate)  aerospanhfa  80 
    Asmanex (mometasone furoate)  asmanex  220 
    Azmacort (triamcinolone acetonide)  azmacort  100 
    Flovent (fluticasone)  flovent 1  44 2  110 3  220 
    Pulmicort Turbuhaler  (budesonide)  pulmicortth  220 
    Pulmicort Flexhaler   (budesonide)  pulmicortfh 1  90 2  180 
    Pulmicort Respules   (budesonide)  pulmicortrp 1  250 2  500 
    Qvar HFA  (beclomethasone dipropionate)  ovarhfa 1  40 2  80 
    Symbicort (budesonide/formoterol)  symbicort 1  80/4.5   2  160/4.5 
Alvesco  alvesco 1  80mcg 2  160mcg 
b. What is your current prescribed daily dose?  (Total puffs per day)  puffsperdaycur
1  1 2  2 3  3 4  4 5  6 6  8 
B.  Other asthma controller medications: 
Do you/your child use or have ever used:  Yes/currently Past use Never taken 
1. Inhaler beta-agonist (Albuterol: ProAir, Proventil, Ventolin,
Xopenex)?  betaagonistih 1 2 0 
      1a) What is your total puffs per day? 
ibapuffs 1  1 2  2 3  3 4  4 5  6 6  8 
2. Nebulized beta-agonist (Alupent soln, Proventil,
Xopenex)?  nebulizedba
1 2 0 
     2a) What is your total nebulized dose per day?  nbadose 
1  1 2  2 3  3 4  4 5  6 6  8 
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Yes/currently Past use Never taken 
3. Oral beta-agonist (Volmax, Repetab) or liquid albuterol?
 oralba 
1 2 0 
4. Long-acting bronchodilator (Foradil, Serevent, Brovana
or Advair)?  lgacbroch
1 2 0 
5. Leukotriene inhibitors (Singular, Accolate, or Zyflo)?
 leukotrieneinhb 
1 2 0 
6. Theophyllines (Theo-dur, Slobid, Uniphyl)?  theophyllines 1 2 0 
7. Ipratroprium bromide (Atrovent or Combivent)?  atrovent 1 2 0 
8. Tiotroprium bromide (Spiriva)?  spiriva 1 2 0 
9. Injectable Corticosteroids (Kenalog, Decadron,
Depomedrol, Solumedrol)?  injcort
1 2 0 
C.  Immunotherapy      immunothrpy Yes/currently Past use Never taken 
Have you/your child ever had allergy shots/immunotherapy? 1 2 0 
D.  Anti-IgE therapy  
Have you/your child ever had Xolair?  xolair 1 2 0 
E.  Alternative Medications 
Have you/your child ever tried any alternative medicines or 
treatments for your asthma such as acupuncture, 
chiropractor, or herbal teas?  altmeds 
1 2 0 
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Medications for Other Conditions 
Yes/currently Past use Never 
taken 
1. Nasal Steroids (Beconase, Flonase, Fluticasone,
Nasocort,      Nasonex, Rhinocort, Vancenase, or Veramyst)? 
nslstrds 
1 2 0 
2. Reflux medications (for GERD)  gerdmds 1           2  0 
2a) Proton pump inhibitors, (Prevacid (lansoprazole);
       Prilosec (omeprazole); Nexium (esomeprazole)  
protpinhb 
1 2 0 
     2b) H2 blockers (Tagamet (cimetidine); Zantac 
(ranitidine);  
  Pepcid (famotidine).  h2blockers 
1 2 0 
3. Osteoporosis/ Bone Density Medications  bonemeds 1 2 0 
4. Antidepressants  antidep 1 2 0 
5. Anti-anxiety medicines (Valium/Ativan)  antianxds 1 2 0 
6. Diabetes Medications (including insulin and pills)  diabtsmds 1 2 0 
7. High blood pressure medications  hbpmeds 1 2 0 
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